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VII. Dermatological Needs in Drugs and Instrumentation 
Control and eradication of skin diseases now prevalent are 
sought in the realms of pharmacology (the science of drug 
action), pharmacotechnology (the science of manufacturing or 
adrrlinistering drugs), and instrumentation. The needs and re-
quirements for dermatology are distinctly different from the 
needs and requirements of other branches of medicine. Devel-
opment of dermatologic drugs and instrumentation therefore 
requires special attention. 
1. DRUGS FOR DERMATOLOGY 
Only 50 years ago a list of major diseases would have included 
a number of skin diseases and diseases manifested in the skin, 
such as parasitic infestations, bacterial infections, syphilis, and 
small pox. Death or impairment from those diseases occurred 
frequently early in life. At the time drug development was 
directed toward control of those infections. With the introduc-
tion of antibiotics, these diseases came under control, and 
attention has shifted to diseases that cause impairment of 
health or death in later life (e.g., cardiovascular diseases and 
cancer). Drug development accordingly has shifted toward con-
trol of these diseases. Unfortunately, many serious skin diseases 
and diseases manifest in the skin still abound. Some cause 
major disabilities; others are still fatal. Diseases such as lupus 
erythematosus, pemphigus, scleroderma, melanoma, and my-
cosis fungoides are among those that are disabling and lethal. 
Others are common causes of physical and emotional impau'-
ments. 
With research emphasis on the development of nonderma-
tological drugs, dermatology has had to be content to use drugs 
developed for control of other diseases, adapting them where 
possible for treatment of skin diseases. One example of such 
drug adaptation is treatment of psoriasis with methotrexate or 
hydroxyurea. These drugs were developed solely for treatment 
of internal cancers, and the risk of toxic reaction is accepta.ble 
for cancer chemotherapy. However, their use in psoriasis is at 
best controversial. Other examples of drug adaptation are the 
treatment of lupus erythematosus with the antimalarial chlo-
roquine and the treatment of pemphigus with antiarthritic gold 
salts_ 
The most widely used drugs in dermatologic therapy today 
are the cortisone analogues. These drugs do not cure; they only 
ameliorate most skin diseases, and thus long-term use is often 
required. A multiplicity of adverse side effects attend long-term 
use, some of which are quite disastrous: such as precipitation of 
cataracts, high blood pressure, softenmg of the skeleton, and 
diabetes. As topical medicaments these drugs are very expen-
sive_ Patients with cm'onic diseases or with diseases involving 
extensive body areas, such as psoriasis and eczema, are con-
fronted with high costs. 
The neglect of dermatologic drugs in today's world is dem-
onstrated in the failure of today's most widely-used textbooks 
of pharmacology and therapeutics to give separate space or 
attention to drugs used for treatment of skin diseases. In these 
texts the dermatologic application of available drugs from other 
fields is mentioned only in passing. 
Dermatopharmacology: A New Discipline 
Development of much needed categories of drugs for der-
matologic diseases specifically will occasion a new discipline, 
that of dermatopharmacology since the methods of general 
pharmacology employed with drugs for internal disease are 
usually of little value for studying drugs for use on the skin. 
A discipline such as dermatopharmacology would provide an 
appropriate place to study many important problems not con-
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sidered in the service of traditional pharmacology and derma-
tology. For instance, it would be highly appropriate for a 
dermatopharmacologist to develop animal models for common 
skin diseases: psoriasis, eczema, pemphigus, ichthyosis, acne, 
warts, and herpes simplex; these models would then be used to 
test new therapies. 
The dermatopharmacologist would be concerned with devel-
oping new drugs and special forms of existing drugs and drug 
vehicles that would be maximally effective when applied topi-
cally. 
Finally, the dermatopharmacologist would be concerned with 
developing ways to protect the skin from environmental as-
saults: from UV radiation, from foreign chemicals, from micro-
organisms, and from physical agents. 
Development of New Drug Categories fOl' Dermatology 
There is now a rational, scientific foundation for the devel-
opment of new drugs, specifically for dermatological disorders. 
There aJ'e 2 categories in which such research should be pur-
sued. The first category-anti-inflammatory and immuno-
modulatory compounds-will be dealt with in detail because 
of the pressing need for such new agents in many areas of 
dermatology. 
1. Anti-inflammatory and immunomodulatory compoun.ds. 
Inflammation. Inflammation is the response produced in vas-
culaJ'ized tissue to noxious physical, chemical, infectious, or 
immunological stimuli. Anti-inflammatory drugs serve to re-
duce the intensity of the inflammatory response and to amel-
iorate the distressing symptoms of inflammation in the patient 
(primarily pain, itch, edema). Inflammation produced as a result 
of stimuli that are internally derived (e.g., auto-immune reac-
tions) is clearly detrimental to the survival of the tissue and the 
host. It is desirable to completely suppress inflammatory reac-
tions of this type. The achievement of this goal requires a 
thorough understanding of the individual components of the 
inflammatory process and a knowledge of the relative signifi-
cance and importance of each of the mediators in each of the 
inflammatory dermatoses. 
A number of mediators of inflammation have been isolated 
from inflammatory lesions of laboratory animals and man: 
biogenic amines (histamine, serotonin); polypeptides (kinins, 
complement components); hydrolytic lysosomal enzymes; lipids 
(prostaglandins and intermediates, thromboxane, SRS-A) ; and 
chemotactic substances (eosinophil and neutrophil chemotactic 
substances of anaphylaxis). The effects of anti-inflammatory 
drugs have been described on most of these mediators with 
respect to inhibition of their biosynthesis or release and com-
petitive antagonism of their pharmacological effects. However, 
the principal mediator(s), the sequence in which mediators act, 
and the synergism of two or more mediators in subacute or 
chronic inflammatory dermatoses have not yet been fully clar-
ified. 
Steroidal anti-inflammatory agents. Prior to 1950, inflam-
matory dermatoses were treated conservatively by nonspecific 
and relatively ineffective regimens involving water baths and 
compresses, often with the addition of oatmeal or aluminum 
salts, "cold" quartz-lamp irradiation, and bland creams or oint-
ments containing zinc oxide, menthol, camphor, phenol, or 
calamine, etc. Tar creams and ointment were used for eczema-
tous conditions and psoriasis. 
A significant breaktm'ough in treating inflammatory derma-
toses occurred in the early 1950's with the introduction of the 
glucocorticosteroids. Chemical modification of the hydrocorti-
sone molecule (e.g., ring halogenation and methylation, and 
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modification of t he 17- and 21-hydroxyl groups) resulted in 
topical drugs with increased anti-inflammatory potency. Syn-
thesis and testing of steroid derivatives over the last 25 years 
have provided no effective topical anti-inflammatory steroid 
preparation devoid of adverse effects and none, other than 
palliative, for chronic disease processes. 
Adverse effects of steroids. Because of the rapid exacerbation 
and qualitative worsening of some chronic diseases, topical 
steroids may be used for extended periods of time, frequently 
with the following adverse effects: atrophy of the skin (partic-
ularly in the geni tal and perianal areas); striae (particularly in 
areas of skin apposition-axillae and inguinal areas); telangiec-
tasia secondary to epidermal and dermal atrophy (particularly 
on the face, neck, and upper chest); steroid acne, steroid rosacea, 
and perioral dermatitis of the face. Of particular significance is 
the report of 12 deaths in the United Kingdom directly attrib-
utable to adrenal suppression following topical use of cortico-
steroids. 
Children are particularly a t risk to the systemic effects of 
topically applied fluorinated steroids in view of their greater 
surface area of body mass ratio. Consequently, percutaneous 
penetration of corticosteroids in children over long periods of 
time can produce adrenal suppression with associated decrease 
in anabolic steroid production. The prevalence of atopic der-
matitis is higher in the 1-12 year old age group (about 17 per 
1,000) t ha n in the 25-74 year old age group (about 4 per 1,000) . 
It is t herefore desirable to develop effective drug treatments for 
this and other inflammatory dermatoses that obviate the ad-
verse effects of corticosteroids. 
Non-steroidal anti-inflammatory agents. Certain acute in-
flammatory dermatoses respond to particular anti-inflamma-
tory agents. For example, dermatoses based upon an immediate 
hypersensitivity reaction frequently respond to antihistamines; 
the acute erythema response induced by UVB can be reversed 
by indomethacin and related nonsteroidal anti-inflammatory 
agents presumably as a consequence of inhibition of prostaglan-
din synthesis; subacute and chronic dermatoses are responsive 
to glucocorticosteroids. A number of topical nonsteroidal anti-
inflammatory agents are marketed in Europe. Most are indi-
cated for arthri t is and minor aches and pains (e.g., benzyda-
mine, Angelini; Tanderil Creme, Ciba-Geigy) ; however, there is 
no convincing evidence that these can substitute for topical 
steroids. 
Screening methods and new anti-inflammatory drugs. An 
assay for drugs of a given therapeutic class attains high pre-
dictability for clinical use when there is similarity between the 
physiologic or pathophysiologic mechanisms of the assay and 
the human disease state. Current assays for nonsteroidal anti-
inflammatory drugs in animals are based on the ability of 
known anti-rheumatic drugs to produce an expected response 
in the assay. Furthermore, the same relative potencies of drugs 
in both the assay(s) and in clinical usage are generally obtained. 
A major problem exists in determining the relevance of an 
an imal assay method to human dermatitis in that no effective 
nonsteroidal anti-inflammatory drug is available to standardize 
the method. Several models of cutaneous inflammation are 
available that respond to topically administered corticosteroids. 
However, most of these measure changes during the acute 
phase of inflammation when the changes are primarily associ-
ated with alterations in vascular permeability. These assays 
suffer a further disadvantage. The anti-inflammatory drug is 
admi nistered before, or concomitantly, or immediately follow-
ing the inflammatory stimulus, i.e., t hese tests are measuring 
prophylactic effects of the drugs. The relevance of this test 
procedure to the treatment of human dermatitis is questionable. 
We need to develop models of inflammation that incorporate 
most of the clinical a nd histopathologic features that many 
huma n dermatitides have in common, i.e., chronicity, mild-to-
moderate scaling, increased epidermopoiesis, epidermal edema, 
and dermal cellular infIltration. Recent studies indicate that 
such models may be on the horizon. Daily application of irri-
tants, e.g., hexadecane to guinea pig skin or sodium laurate to 
rat skin, produce responses that superficially meet some of the 
above criteria. Standard nonsteroidal anti-inflammatory drugs 
(aspirin, indomethacin, phenylbutazone) were compared with 
corticosteroids (hydrocortisone, fluocinolone acetonide) as to 
the epidermal hyperplasia component of the inflammatory re-
sponse, and it was found that 1% indomethacin was equivalent 
to 1% hydrocortisone. The validity of this assay must be ques-
tioned, however, because the utility of indomethacin in the 
treatment of human dermatitis appears to be limited to the 
relief of pain and erythema associated with sunburn. It may be 
that anti-epidermopoietic effects are a necessary but not a 
sufficient requirement for anti-inflammatory activity in human 
dermatitis . 
A deficiency of essential fatty acids in the diet produces a 
scaling dermatitis in the rat. Corticosteroids reduce the rate of 
epidermal hyperplasia, and scaling can be cleared by topical 
PGE2 or arachidonic acid. This may serve as a satisfactory 
model for some human inflammatory dermatoses in view of 
reports that inhibitors of prostaglandin synthetase are present 
in homogenates of skin obtained from lesions of atopic derma-
titis, allergic contact dermatitis, cutaneous lupus erythemato-
sus, and psoriasis. 
The involvement of prostaglandins in various types of inflam-
matory lesions is still under investigation. It is reasona ble to 
assume that the effects of prostaglandins are of consequence in 
the inflammatory process associated with rheumatoid arthritis. 
However, the great capacity of epithelial tissues to synthesize 
prostaglandins suggests that prostaglandins may have a homeo-
static function in the epidermis in addition to their indispens-
a bility in the process of keratinization. The potentiation by 
prostaglandins of other mediators (histamine, bradykinin) to 
increase vascular permeability appears to be influential in the 
acute inflammatory response. Clearly, the significance of pros-
taglandins in dermatitis must be clarified before fully rational 
approaches to the design of anti-inflammatory drugs for der-
matoses can be undertaken. 
Corticosteroids have effects on most aspects of the inflam-
matory response, whereas current nonsteroidal anti-inflamma-
tory drugs usually are effective only in the early phases of an 
acute inflammatory response. The nonspecificity of the corti-
coids may be the reason why they are effective in a wide variety 
of inflammatory diseases. It is reasonable to assume that a 
nonsteroidal drug may have an effect on only 1 or 2 dermati-
tides, not on all steroid responsive dermatoses. 
Needs for additional research. One way to obviate the side 
effects of corticosteroids might be to develop drugs with specific 
mecha nisms of actions for specific inflammatory diseases of the 
skin. The topical use of sodium cromoglycate in atopic derma-
titis is to the point. If it is effective, derivatives that might be 
more suitable for percutaneous penetration should be studied, 
together with other compounds that interfere with mediator 
release. 
Dapsone, 4,4' -diaminodiphenylsulfone, has specific utility in 
the treatment of dermatitis herpetiformis .. Its mechanism of 
action should be defined and other derivatives should be stud-
ied. 
Effort should be directed toward development of more rele-
vant animal models of chronic inflammation. Some dermatoses 
are described in veterinary medicine that may be sufficiently 
close to the human disease state to warra nt their use in screen-
ing programs.' In those diseases that appear to be genetically 
predisposing, it would be worthwhile to initiate animal breeding 
programs to increase the incidence of those diseases in offspring. 
The use of irritant and immunological stimuli is an appropri-
ate approach for the study of inflammation in otherwise normal 
skin . Alternatively, combinations of nomeostatic agonists and 
antagonists could be used (i.e., beta-blockers and histinase H-2 
agonists). 
It is important to continue investigation of the biochemical 
and physiological charges occurring in human inflammatory 
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disease as well as the mechanisms that trigger and perpetuate 
t h e diseases. Major advance will result if studies are done in a 
research setting where patients could be closely observed, drug 
application closely controlled, and biochemical and immunolog-
ical studies could be performed. Obviously this will require a 
clinical research setting and close cooperation with basic sci-
en tists. Careful consideration of safety and careful control of 
application of new compounds to small skin areas should permit 
the acquisition of much needed baseline data. Cost savings 
through the use of Investigational New Drug screening proce-
dures, modified to permit careful topical testing, would be 
e normous. 
2. Compounds to modulate keratinization: The process 
whereby integumental epithelium forms a tough surface layer, 
stratum corneum, that serves the life-sustaining function of 
protection against noxious physical and chemical agents is 
called keratinization. It appears to be a primitive function of 
most epithelia. It is now known to be modulated by 2 groups of 
chemical substances, vitamin A and its analogs (collectively 
known as retinoids) and alpha hydroxy-keto acids. 
V itamin A. This substance seems to be preeminent in phys-
io logic control of keratinization of most epithelia of the body 
since, in vitamin A deficiency states, keratinization occurs in 
normally nonkeratinizing epithelia, e.g., conjunctival, uterine, 
etc. 
The retinoids. These compounds are operative in the physi-
ology of epithelium, not only of the skin but also of the respi-
ratory tract, breast, bladder, and other tissues. Some of these 
compounds are synthetic derivatives that have been therapeu-
tically effective in experimental anin1als and have reversed 
various hyperprolifera tive skin diseases in human patients. The 
use of retinoids has a sound basis in a large body of work in 
experimental animals and in man. It is clear that retinoids are 
essential for the normal cellular differentiation of skin epithe-
lium, neoplasms of which account for more than one-half of the 
total primary cancers in both men and women. When retinoids 
are given to experimental animals, the progression of preneo-
plastic lesions can be halted and even established tumors can 
be stabilized, arrested, and actually reversed. If animals are 
given carcinogens that ordinarily result in production of cancer 
of the skin, the bladder, or other organs (the site depending on 
where the carcinogen is introduced) the administration of reti-
noids will almost completely prevent the development of the 
t umors. 
Both ingestion and injection by needle of various retinoid 
compounds have prevented the formation of anticipated can-
cers in the skin of animals to which carcinogens have been 
applied. The normal tissue distribution of the naturally occur-
ring retinoids is inadequate for their practical usefulness in the 
prevention of cancer. Their toxicity at high dosage levels argues 
against their use. Less toxic synthetic compounds can be man-
ufactured that have more powerful antitumor effects. Certain 
natural retinoids other than vitamin A seem to show promise 
of being less toxic and more active. It is not known as yet 
whether the synthetic retinoids will have a practical use in the 
prevention of cancer in humans. It is likely that experimentation 
with their use will uniquely contribute to a better understanding 
of epidermal disorders, both benign and malignant, and their 
pharmacologic control. 
Alpha hydroxy-keto acids. In hyperkeratotic conditions, such 
as ichthyosis, and in other conditions characterized by "dry 
skin," alpha hydroxyketo acids have been able to modulate 
epidermal keratinization. The means by which this is done is 
unknown. Perhaps they act upon the attachment of stratum 
corneum cells to each other since in many of the hyperkeratotic 
disorders the thickened stratum corneum seems to be a result 
of increased intercellular adhesion. 
It is important to pursue studies of how the 2 groups of 
compounds, both of which appear to modulate keratinization 
physiologically, exert their effect on the normal and the dis-
eased epidermis. Since they are natural regulators of epit helial 
function , some members of either group may come close to 
realizing the ideal pharmacologic agent. It would be unfortunate 
to not explore fully their role in normal epithelial control and 
their potential as a therapeutic modality for control of disturbed 
epithelial function. 
Developing Drugs of Limited Commercial Value for 
Uncommon Diseases 
Although consumers spend billions of dollars annually for 
preparations to apply to their skin (both for its normal care and 
for the treatment of abnormalities and disease) an astonishingly 
small amount is spent to develop improved topical preparations 
for the treatment of skin disease. It is the attitude of most 
phaTmaceutical companies and government agencies, with a 
few exceptions, that almost all of dermatologic drugs have 
"li ttle commercial value." Consequently a number of drugs 
known to be of potential therapeutic utility are not available in 
t he usual marketplace. 
Following are examples of dermatologic drugs that should be 
but are not available in the United States because of limited 
commercial value. In some cases, there may be other reasons 
for their unavailability. 
1. Thiabendazole: Creeping eruption is a distressing and 
often disabling condition caused by dog hookworm that is 
contracted fyom contact with infected soil. It is widespread in 
warm climates. It occurs in the southeastern United States 
from the coast of Texas to North Carolina and is particularly 
prevalent in Florida. Although an oral preparation of thioben-
dazole is available, adequate dosage usually causes gastrointes-
tinal distress with nausea and vomiting. It has been known for 
over 10 years that thiabendazole, when applied externally to 
the skin, is effective for curing the hookworm infection promptly 
and easily. Nonetheless no topical medication is available fo r 
such use and no claims for its topical use have been made by 
the manufacturer. Physicians, reluctant to prescribe the medi-
cation topically, have been using it orally because this is the 
officially-approved method of administration. 
2. Pimaricin: Fungal keratitis is one of the most serious 
infections of the eye because, if untreated or unsuccessfully 
treated, it usually results in blindness. It is estimated that there 
are over 300 cases or more in the United States per year, a 
significant proportion of which are in the southeast. The yeast 
Candida albicans often and, more commonly, fllamentous 
fungi, such as Fusarium and Aspergillus, are the cause, espe-
cially in vegetable and citrus fruit -growing areas. After trials 
with a variety of antifungal agents, both available and unavail-
able in the United States, it was found that the antibiotic 
Pimaricin was by far the most effective. A series of patients 
treated with this experienced spectacular clearing of the infec-
tion and retained normal vision. Nonetheless, the drug, made 
in Belgium, is not available from any commercial source in the 
United States. It can be obtained "informally" from the Oph-
thalmology Departments of the University of Miami or of 
Louisiana State University. Because this drug seems to be more 
efficacious than its related congeners, such as Nystat in and 
Amphotericin-B, it might be effective in sites of fungal infection 
other than that of the eye. 
3. Dapsone: It has been known for many years that t he drug, 
DDS, or diaminodiphenylsulfone (Dapsone), developed origi-
nally for the t reatment of leprosy, is also effective for the 
treatment of dermatitis herpetiformis and several other rare, 
disabling and chronic skin diseases. DDS has been shown 
recently to have anti-inflammatory properties, particularly 
against the mediator bradykinin, which may account for some 
of its therapeutic activi ty. Because there are almost no other 
anti-inflammatory drugs that have distinctive anti bradykinin 
effects, it seems inexcusable that DDS should be denied. In the 
CO UTse of a large screening effort to find better antimalarial 
drugs, the Uni ted States Army fou nd that a derivative of DDS 
known as diformyl dapsone was much more effective than the 
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dapsone itself. To our knowledge, there has been no attempt to 
investigate this drug further either for several skin conditions 
for which dapsone (DDS) is now used or for the treatment of 
leprosy, which still afflicts tens of millions of people around the 
world. 
4. Corticosteroid lozenges: For many years, it has been 
known that severe canker sores, erosive lichen planus, and some 
other forms of stomatitis in which chronic or recurrent, painful 
lesions in the mouth often make it difficult or impossible to 
take fluids and food will respond to treatment with cortico-
steroids. It has been noted that certain corticosteroids applied 
topically in the mouth are effective. No commercial lozenge has 
been made. It has been shown that certain types of cortico-
steroids are much better than others for this purpose. They 
exert most of their effect at the site of application, thus avoiding 
the side effects caused by absorption in the bloodstream. The 
lozenge need not have the unpleasant taste of many cortico-
steroids because palatable candidates are available, such as 
betamethasone valerate, already sold in the United States in 
forms other than for use in the mouth. 
5. Methenamine: Occasional patients have extreme hyperhid-
rosis in which the palms or soles of the feet drip sweat to not 
only an embarrassing but also to such a disabling extent that 
they are unable to work with fine machinery or to wear ordinary 
shoes. For many years the topical form of methenamine has 
been available in Europe for treating hyperhidrosis. The appli-
cation of this drug in simple solutions of water or alcohol or as 
a cream is highly effective and only very rarely causes any 
adverse reactions. Patients in the United States with this con-
dition are being deprived of a useful remedy. 
6. Dimers of linoleic acid: The forms of linoleic acid that are 
commercially available are a dimer, a trimer, tetramer acids, 
and a number of salts of these compounds. It has been shown 
that fatty acid dimers and salts of the compound reduce skin 
irritation from various detergents and irritants. In particular, in 
a number of careful studies in which people known to be allergic 
to poison ivy were exposed to poison ivy leaves or extract after 
application of a salt of the dimer, the anticipated reaction was 
almost completely prevented. To a number of people who work 
outdoors, such as road maintenance men, telephone lineman, 
foresters, gardeners, etc., a preventive preparation would be 
most helpful and probably would be used regularly. Individuals 
highly sensitive to the Rhus family, including poison ivy, might 
be sufficiently concerned to apply the preparation whenever 
there was a potential exposure to the antigen. The preparation, 
nonetheless, is not available for topical use in the United States. 
Need for studies on drug availability: The informal, often 
voluntary, channels of distribution of otherwise unavailable 
drugs are not satisfactory. Regular commercial sources would 
ensure adequate supply of t he drug and uniform and appropri-
ate quality. Although the existing "Parasitic Disease Drug 
Service" of the Center for Disease Control is often lifesaving in 
providing 10 nonapproved drugs for rare, tropical parasitic 
diseases that do occur in the United States from time to time, 
this approach actually circumvents the unde'rlying problem and 
is certainly not a workable solution for distributing dermatolog-
ical drugs. A permanent Investigational New Drug status, to 
circumvent commercial sources of supply, seems equally un-
workable for the kinds of drugs used in dermatology. 
Support, from NIH or other sources, should be sought for a 
detailed study of the factors that affect drug availability. Re-
alistic recommendations and action should follow. It is probably 
an oversimplification to attribute the unavailability of drugs 
solely to limited sales prospects; it well may be necessary to 
change laws. Factors that firms have to take into account when 
deciding whether to market a drug, in addition to the extent of 
its use, are patents, legal ability for clinical drug testing, gov-
ernment sponsorship of development of the drug or government 
or foreign-owned patents of a drug, etc. For example, a drug 
firm's liability insurance rarely pays the damages awarded a 
patient injured as a result of receiving an investigational drug. 
When paid by the ftrm, the damage payments are usually 
charged to the drug development cost, one more element in the 
initial cost the sponsor must take into consideration before 
embarking on the development of the drug for which only a 
limited market is anticipated. 
Attempts could be made to decrease the cost of developing, 
marketing, and distributing a drug of limited commercial value 
by: (a) elimination of a substantial amount of animal tests 
before careful limited trials in man for topical agents, (b) 
establishment of a scientific appeal board, including nonFDA 
members, to review the requirements of NDA (New Drug 
Application) for drugs of limited commercial value, (c) where 
necessary, government sponsorship if studies required for NDA 
defense of drugs of limited commercial value, and possibly a 
tax incentive for ftrms willing to develop and market drugs of 
limited commercial value. 
Development of New Vehicles and Delivery Systems for 
Topical Drugs 
There is great need to develop new systems for delivery of 
topical therapy in proper amounts to appropriate layers of the 
skin at appropriate rates. Current vehicles for topical drugs are 
very inefficient and only marginally effective in delivering their 
active ingredients to the site of disease. Only small portions of 
topical dosages actually penetrate the skin. This simple failure 
results in much waste of expensive ingredients lost to the 
clothing or bathwater of patients. Somewhat conversely, a few 
topical vehicles are wasteful because the drug passes through 
the skin too fast, and much of the drug is eliminated systemi-
cally. There is sufficient evidence today that the existing phar-
macologic agents could achieve greater proficiency if they were 
are coupled with properly designed and formulated delivery 
systems. The scientific basis for development of better delivery 
systems is adequate; it is the knowledgeable workers in this 
area that are lacking. The training of competent new workers 
and leaders at this time is vital. 
1. Need for studies on drug bioavailability: "Bioavailability" 
is a term used to indicate the rate and total amount of drug or 
drug metabolite(s) that reaches the site of action following 
topical application. Many biological, physical, and chemical 
phenomena can affect the bioavailability of topical drug prod-
ucts; each is a relatively little explored but necessary area for 
research. 
Effect of skin disease on absorption. It must be recognized 
that the bioavailability of topically administered drugs is highly 
dependent on the integrity of the skin to which it is applied. 
Both the rate and the extent of percutaneous absorption depend 
upon the condition of the stratum corneum. When the integrity 
of the stratum corneum is damaged by various disease pro-
cesses, bioavailability changes. Very little is known concerning 
the permeation of diseased skin and still less concerning the 
rate at which the skin barrier is repaired during the healing 
process. Such information could result in drug formulations 
designed to anticipate the altering nature of the skin barrier in 
specific diseases and could provide data to tailor formulations 
for specific diseases. 
Pharmacodynamics. Research is active in orally adminis-
tered drugs, their pharmacodynamics, the study of their ab-
sorption, their distribution, their metabolism, and excretion of 
their substances. However, relatively little research effort is 
expended on these vital processes for drugs administered topi-
cally. Yet it is precisely this area of research that offers the 
most promise for insight into some of the perplexing differences 
in the efficacy of topically and orally administered drugs. For 
example, although methotrexate is beneficial for psoriasis when 
administered systemically, most workers have been unable to 
show significant effects when it is applied topically. It is well-
recognized that the slow, perfusion-like delivery of topical drugs 
is qualitatively different from the rapid absorption of oral or 
systemically administered drugs, yet the effect of this qualita-
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tive difference on drug efficacy has received essentially no 
attention. Both the metabolism and distribution of drugs pre-
sen ted topically could be very different from those of oral 
administration in specific instances. Much more basic research 
in these areas is needed in order to rationally design more 
effective topical formulations. 
E ffect of drug vehicles. The rate of percutaneous absorption 
of a drug greatly depends on the nature of a pharmaceutical 
vehicle in which it is presented. A drug administered at a 
potentially effective concentration can be rendered completely 
ineffective by an inappropriate vehicle. The vehicle can exert 
this influence indirectly by affecting the partition coefficient of 
th e drug or directly by affecting the physical properties of skin, 
e .g., by promoting hydrat ion (occlusive or aqueous vehicles), by 
solubilizing skin lipids (organic solvents) , by disrupting skin 
keratin (surfactants) or by other mechanisms. Mixed vehicles 
or complex vehicles are poorly understood, yet they are widely 
used in both the pharmaceutical and cosmetic industries. Ex-
amples are hydroalcoholic vehicles and hydropropylene glycol 
vehicles. 
Specialized needs exist in specific therapeutic categories. 
Vehicles that increase the rate of penetration without damaging 
the skin, "penetration adjuvants," would be particularly valu-
able when the very potency of the drug limits the amount that 
can be used. Vehicles that would increase the bioavailability of 
anticomedogenic drugs within acne lesions are needed . Vehicles 
designed to produce and maintain high concentrations of active 
drug near the skin surface should be developed for sun screens, 
antifungal agents, and antimicrobial agents. For such purposes 
absorption is unnecessary, even undesirable. 
Metabolism of drugs in the skin. A topically applied drug 
may not be effective, at least in the way anticipated, if it is 
metabolized while in transit through skin. Very little is known 
about the metabolism of drugs by skin, although studies with 
steroids and some carcinogens indicate that active metabolism 
by t he skin does occur. It has yet to be shown that active 
metabolism of a drug occurs in the skin during percutaneous 
absorption. S uch studies would clearly be of significance to 
topical therapy since they would reveal whether the drug is 
converted to a more active or to a less active form. 
An importa nt corollary to this work is the potentially differing 
metabolism of topically and orally administered drugs once 
t h ey enter the circulation. The initial bypassing of the portal 
circulation by cutaneously absorbed substances admits the 
possibility of metabolites different from those obtained by 
systemic administration of the same drug. Since detoxification 
pathways for t hese 2 routes may be different, it may be a serious 
error in some instances to rely on metabolic data generated 
frOIn ingestion studies when developing topical drugs. 
Effect of skin permeability. Recent advances give some hope 
that it may soon be possible to predict the extent of percuta-
neous absorption from a knowledge of the chemical properties 
of the drug. The ability to predict the concentrat ion of the drug 
in the skin or in the blood would be of obvious benefit in the 
development of safe and effective topical formulations. Because 
of the substantial cost of the toxicological and clinical studies 
required to bring a drug to market, there is a very real need to 
select the best formulation as early in the testing as possible. 
Research necessary to fill gaps in our present knowledge 
includes both in vitro laboratory studies and in vivo measure-
ments of permeation rates in man. In both instances the em-
phasis should be placed on obtaining carefully documented 
quantitative data on the effects of drug structure, solubility, 
vehicle type, concentration, and manner of application. 
More in vivo permeation studies in man are particularly 
necessary. Only with such studies can we test and validate 
theoretical models for predicting permeation. This work can 
bridge the gap between laboratory in vitro studies and appli-
cation to the patient. 
2. Needs for improvement of vehicles: The following classes 
of therapeutic agents contain compounds that are effective 
therapeutically when applied topically. If vehicles were im-
proved, the compounds would be even more effective. 
Anti·inflammatory compounds. The glucocort icosteroids are 
widely used for the treatment of specific types of inflammation 
of t he skin . Unfortunately, they have adverse local effects on 
cell membranes and interfere with collagen formation and vessel 
function. If vehicles could be developed that appropriately limit 
the release ofthe drug, minimal effective doses with correspond-
ing minimal adverse effects could be prescribed. 
Local anesthetics. A number of local anesthetics are available 
including the "Caine" variety. Topically applied anesthetics are 
effective where t he skin is broken; their penetraf;ion through 
unbroken skin is variable and their effect limited. If the vehicle 
could be improved to increase the penetration of unbroken skin, 
the anesthetic would be more effective in t he treatment of pain 
and make possible local skin surgery without injections. 
Topical antifungals. Many chemical compounds possess in 
vitro antifungal activity and are acceptable for topical applica-
tion. In topical use only a few of them have shown therapeutic 
value. In most instances the action of topical antifungals is 
relatively slow. Again, if the vehicle could be made to speed the 
antifungal to the site of infection, a more rapid clearing of 
lesions would follow. 
Historically, undeclyenates have been used for the derma to-
phytes and the polyenes, such as nystatin, for Candida infec-
t ion. More recently the imidazole topically applied antifungals, 
such as micronazole and clotrimazole, have become available 
and are effective against both. Tolnaftate is effective against 
the dermatophytes only. Even though there are no valid sci-
entific data to determine the relative efficacy of these com-
pounds, more penetrating delivery systems wou ld surely in-
crease their value. 
Other drugs. Adenine arabinoside, an antiherpes compound; 
is useful in herpetic eye lesions. If this drug were held in an 
improved or possibly in a different vehicle, its use might be 
extended to other integumental herpetic infections. 
A wide variety of anticancer compounds are available for oral 
and systemic use. Fluorouracil is used topically for the treat-
ment of solar keratoses. Appropriate vehicles may make this 
compound and others easier to use. 
Keratinolytic agents, such as salicylic acid, are available in 
vehicles of various combinations. Slow release vehicles or those 
maintaining close proximity of the compound to the skin may 
make salicylic acid more effective. 
Peeling agents, topical antibiotics, and retinoic acid are avail-
able for treatment of acne. Improvement in vehicles would 
improve their effect and deliver exact amounts of the drugs to 
the skin. . 
3. Needs for Research on the Design of New Vehicles: 
Powders, creams, and lotions. Powders are currently used as 
passive delivery systems. Consideration should be given to 
active powder systems such as those used in "cephadex electro-
phoresis columns" that would release or deliver drugs at various 
rates determined by their composition. Such powders would 
have particular application in moist lesions, ulcers, and wounds. 
Research on new creams and lotions should also give consid-
eration to new ingredients that would release active ingredients 
at regulated rates. 
Films, adhesive masses, and microcapsules. Other ways to 
regulate t he rate of delivery of a product to the skin or maintain 
it at the site for slow release should be explored. Films are 
another material available for this purpose. Carboset mms hold 
drugs and remain on the skin for prolonged periods. They can 
be readily removed with alteration in skin pH. Other films 
could be developed with similar characteristics. Hydrogels have 
the capacity to hold water and could be used for sustained drug 
release. Other kinds of films could be developed to release drugs 
at different rates. Cosmetically acceptable films that hold and 
maintain sunscreens in place for as long as necessary are needed. 
Adhesive masses are available into which sui table drugs could 
be incorporated. The masses can be covered by backings that 
regulate water transmission so that hydration of the skin could 
be altered. 
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Drugs can be microencapsulated. The capsules can be made 
of materials that disintegrate at rates determined by the local 
conditions and by the size of the capsules. Drug efficacy could 
be prolonged in this manner. 
Protective vehicles. As mentioned, dimers of fatty acids bind 
to the active components of poison ivy and make the primary 
irritants and the allergic components less noxious. Research in 
this area could develop compounds that would bind with other 
primary irritants and noxious irritants encountered by the skin. 
Modifying the skin to change absorption. DMSO is a chem-
ical that penetrates readily through the skin and, when applied 
with chemical compounds, permits their greater penetration. 
Analogs of DMSO achieve similar results. Further research is 
needed on compounds which enhance penetration by altering 
the stratum corneum barrier. 
Nitrites are absorbed rapidly through the buccal mucosa. 
Their value in penetrating the skin and in assisting penetration 
of other compounds should be studied. 
Iontophoresis is an old and neglected method for forcing 
charged molecules through the skin with an electric current. 
With today's improved electronic technology it should be pos-
sible to develop new and sophisticated devices for quantitative 
delivery of drugs by iontophoresis. 
Developing Procedures for Early Low·Risk Testing on 
Human Shin 
No experimental animals have been found to have many of 
the common skin disorders that afflict humans. The models of 
human disease that have been sought in biologic systems rarely 
have proved to be valid models. They are inadequate to screen 
drugs for beneficial effects on human skin disorders. For ex-
ample, because psoriasis is characterized by excessive epidermal 
mitosis, biologic models displaying high rates of mitosis, such 
as normal mouse vaginal epithelium or mouse epidermis that 
has been exposed to ultraviolet radiation, have been used to 
screen antimitotic drugs for topical agents in its treatment. 
Simila rly, because elevated levels of cyclic AMP hypothetically 
suppress mitoses, phosphodiesterase inhibition has been used 
as a biochemical model for the same purpose. Neither model 
has proved valid in selecting topically efficacious agents, al-
though some drugs do in fact inhibit mitosis. This property 
alone seems insufficient. At present the only valid model of 
psoriasis is psoriasis itself, probably because the fundamental 
nature of biologic and biochemical determinants of this disease 
have not yet been discovered. 
A similar circumstance prevails in the ichthyoses, disorders 
of keratinization with grotesquely thickened hyperkeratotic 
stratum corneum as a characterizing feature. Animal models, 
such as the hairless mouse and the variant known as the rhino 
mouse, which have thickened hyperkeratotic stratum corneum, 
fail to reveal the activity of alpha hydroxy-keto acids as effica-
cious agents, although they are clearly effective in patients. 
Only by topical testing directly on patients with ichthyosis can 
the therapeutic activity of these agents be detected. 
A similar circumstance obtains in many other skin diseases, 
such as acne, Darier's disease, pityriasis rubra pilaris, epider-
molysis bullosa, mycosis fungoides, exfoliative erythrodermas, 
types of eczema, vitiligo, and others. 
From actual experience and by objective computation, there 
is eve ry reason to believe that candidates for therapeutic agents 
can be tested for efficacy on confined small areas of the skin in 
patients with such diseases with a minimal risk of systemic or 
local adverse effects. Under prevailing regulatory constraints, 
topical testing of potential therapeutic agents developed by 
pharmaceutical firms for the foregoing diseases requires enor-
mous expenditure of funds, time, and effort. The likelihood of 
identifying a successful therapeutic agent in animal models or 
by laboratory tests is very small. It would cost over $20 million, 
and consume 100 years of effort by a single institution or firm 
to test 10 potential therapeutic agents (Table 1). 
TABLE 1. 1978 cost of developing a new topical drug 
The following table is provided to illustrate some economic reasons 
why drugs for many relatively uncommon skin diseases fail to be 
developed. This cost analysis was made on the assumption that the 
hypothetical new drug is a new chemical compound. 
31ft years 
1 year 
21ft years 
2 years 
Activities and stage Cost 
Phase I 
Discovery, biology, pharmacology, $0.6 million 
toxicology to Investigational New 
Drug (lND) 
Early Phase II 
IND to decision point: for or against $0.3 million 
New Drug Application (NDA) 
Late Phase II 
Complete long-term laboratory and $1.2 million 
clinical studies 
Final FDA approval 
Total Time: 9 years 
Total Cost: $2.1 million 
There is a need for changes in the federal regulations in order 
to facilitate early topical screening of candidate compounds on 
human skin. Screening procedures could be carefully defmed to 
assure minimal risk of developing adverse local and systemic 
effects. The Food and Drug Administration should be urged to 
tailor their safety and efficacy requirements to products that 
are to be used on the skin. In particular, the development of 
new drugs for topical use could be greatly hastened if small 
amounts of the drugs incorporated into the usual vehicles could 
be applied and the effects studied on tiny areas of human skin. 
Such a simple expedient would give valuable information on 
the biological activity of the drug in man and an indication as 
to whether further developmental work, including expensive 
animal studies is required or even worthwhile. The present 
requirement that an inordinate amount of animal testing for 
toxicity has to take place before even a tiny dab of the cream 
can be applied to a patient under close medical supervision 
effectively prevents the development of many new drugs and is 
an example of waste of the limited facilities and people available 
for dermatologic pharmacology. 
Adverse Drug Reactions 
An adverse drug reaction is any response to a drug that is 
noxious and unintended and that occurs at doses used in man 
for prophylaxis, diagnosis, or therapy, excluding failure to ac-
complish the intended purpose. Many adverse drug reactions 
may be confined solely to the skin. Few families have escaped 
the unpleasant experience that an adverse cutaneous drug 
reaction can induce. Most physicians have provoked a cuta-
neous drug reaction or have observed and/or treated a patient 
with such a problem. 
1. Prevalence and severity: The general problem. Numerous 
references have appeared in both lay and professional publica-
tions during the past few years purporting to discuss the prob-
lem of adverse drug reactions. "Thousands a Year Killed by 
Faulty Prescriptions" reads a New Yor/z Times headline in 
1976. "Drugs Remarkably Nontoxic" is the title of a paper 
appearing in the New England Journal of Medicine (from 
which many of the statistics used in the New York Times story 
were obtained). The truth probably lies between these 2 views. 
There is little doubt that adverse drug reactions cause several 
thousand deaths each year; that they necessitate hospital ad-
mission or prolong the hospital stay; and that they create an 
enormous annual expense, perhaps in the billions of dollars. 
The data, however, are incomplete, unrepresentative, uncon-
trolled, or lacking in operational criteria for identifying adverse 
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drug reactions. One thing seems certain , however. The available 
statistics probably underestimate the costs of dealing with the 
problem of drug reactions. 
Cutaneous reactions. Since 1966, data relating to drug effects 
on over 20 thousand medical inpatients has been collected in a 
large collaborative drug surveillance program. Allergic skin 
reactions to drugs have occurred in slightly over 2%, a figure 
that agrees with prior estimates of 2- 3% in medical inpatients. 
Despite the lack of data on non hospitalized patients and 
limited data on selected hospitalized patients, it is clear that 
even if only 2% of patients receiving drugs experience a cuta-
neous reaction, it is a huge number since almost everyone in 
the nation uses drugs. 
2. Status of research: Cutaneous drug reactions are complex. 
There is a range of reactions from immediate, occurring within 
seconds to minutes following administration of a drug, to sub-
acute, beginning days to weeks after a drug is administered, to 
chronic, occurring years later. Some reactions are transient, 
such as itching or hives that sometimes follow intravenous 
injection of iodinated x-ray contrast material; others are per-
manent, such as the disfiguring skin pigmentation that may 
follow the use of certain silver-containing medications. Some 
reactions clearly have an allergic basis, such as the widespread 
reaction to penicillin that occurs within minutes to days follow-
ing administration; others produce effects by less clear mecha-
nisms, possibly allergic, such as procainamide-induced lupus 
erythematosus that occurs after months of use; and still others 
act by unknown mechanisms, probably nonallergic, to produce 
effects 20 years after administration, such as arsenic-induced 
keratoses and skin cancers. 
The severity of clinical cutaneous drug reactions is quite 
variable. A drug reaction can produce only mild transient 
discomfort (itching and unsightly skin eruption), or it can cause 
discomfort and morbidity for many days and weeks, or it can 
be severe and fatal (toxic epidermal necrolysis in which the 
entire skin is shed). Changes in hair and nail growth or loss of 
these structures, predisposition to certain skin infections, pho-
tosensitization, response to direct contact of a drug (rather than 
that induced by internal treatment), bleeding in the skin, and 
atrophy of the skin are further variations in cutaneous drug 
reactions. 
Drugs may induce skin changes that are identical to symp-
toms of certain serious systemic diseases, such as lupus erythe-
matosus, lymphoma, or porphyria. 
To further complicate the problem a single drug may produce 
widely differing reactions in different individuals whereas 
widely differing drugs may produce a single pattern in different 
individuals. Certainly, there is almost no drug that has not been 
associated with a presumed adverse cutaneous response. 
What t hen can the clinician do when faced with a patient 
who develops a skin rash while receiving a variety of drugs? 
Unfortunately, very little. With the single exception of penicil-
lin, where reasonably reliable skin tests are available, there is 
no availa ble methodology to predict adverse skin reactions; 
there is no objective method to establish causality by a given 
drug; the victim and often the physicians involved are amazed 
to learn that t here is no "test" to "prove" which drug caused 
the reaction. There are few ways of aborting or decreasing the 
total dura tion of the reaction. The systemic administration of 
antihistamines and/ or corticosteroids may alleviate many of 
the symptoms of some drug reactions incompletely and not 
without risk. 
3. Need for additional basic research: Differentiating of 
allergic from non allergic reactions. The diagnostic criteria for 
an allergic-type drug reaction are by no means precise. More-
over, drug allergy is the one category of allergy in which (with 
certain exceptions) antibodies cannot be directly or indirectly 
demonstrated in many cases. Cutaneous allergic drug reactions 
may be produced and reproduced thereafter by minute amounts 
of a drug that may have been well tolerated for years. Patients 
may have a specificity to t hat one drug or closely related 
chemical derivatives of t hat drug. There may be incubation 
periods dUTing which sensitization OCCUTS, spontaneous flare-
ups, and subsequent altered responses on re-exposure. Despite 
these general considerations, more precise methods are needed 
for differentiation of allergic from nonallergic drug reactions. 
Prediction and prevention of reactions. Each individual is 
exposed to differing pharmaceutical preparations of a drug and 
multiple drugs, often concomitantly with many chemicals in 
the environment. The drug is absorbed into the organism (often 
by different routes of administration) and distributed to the 
t issues, where varyin g amounts are bound to different body 
sites. The drug may be chemically altered by metabolic proc-
esses within the individual, and this chemically-altered material 
can also be bound to various tissues. Finally, the drug must be 
eliminated from the body. 
Many factors alter the details of these processes: the age and 
sex of the patient; the particular genetic constitution of the 
individual ; t he effect of the disease state on the person's ability 
to handle a drug; biologic rhythms, such as the menstrual cycle 
or circadial patterns; the particular environment (microorgan-
isms, radiation, temperatUTe, and humidity); coexistent infec-
tion; in1mune suppression; hyperactivi ty; pregnancy; nutritional 
state; and degree of pigmentation. A precise method is needed 
to meaSUTe and evaluate these factors in a screening test prior 
to drug administration. With such knowledge it might be pos-
sible to avoid or prevent many untoward drug reactions. 
Direct application of drugs to the skin may produce adverse 
allergic or non allergic skin reactions. Although safe and effec-
tive methods are available for the prediction of the occurrence 
of such reactions on a population basis, the prediction of such 
effects for an individual patient is rarely possible, except by 
tedious and time-consuming patch tests. More efficient meth-
odology is needed for the prediction of adverse reactions from 
topically applied drugs. In particulru·, considering t he long r~c­
ord of safety of applying small amounts of drugs to normal and 
diseased skin and the complete lack of any serious systemic 
reactions, this type of drug testing should be exempted to some 
extent from the rigid requirements for paperwork and FDA 
approval required for testing of systemic drugs. 
Methods for isolating the offending drug. Methods are 
needed to determine which drug, of many that a patient has 
taken or is taking, is the cause of the reaction. These may 
include statistical analyses to assess probability of cause for 
different drugs, and skin tests or in vitro methods to detect 
unusual responses. 
Cooperative efforts with immunologists are needed in the 
development of rapid screening methods for an individual's 
pru·ticular immune posture at a given moment. By a combina-
tion of skin tests and in vitro studies, a physician should be 
able to determine in advance t he state of humoral and cellular 
immunity to a drug, its metaboli tes, and conjugates of these 
with proteins or other bodily components. Such work presup-
poses complete cooperation by the pharmaceutical industry in 
making available t he various drugs and their metabolites for 
such investigations. Even if the reaction cannot be an antici-
pated, such technology should certainly be available post ipso 
fa cto to pinpoint the causative drug. 
For nonallergic skin reactions, support is needed for studies 
in basic biochemical phru·macology, pharmacogenetics and clin-
ical pharmacology in an attempt to uncover the individual 
factors that may predispose to a cutaneous drug reaction. A 
prototype of such a study recently appeared in which the 
induction of t he lupus syndrome in humans was related to the 
rate at which the subject metabolized t he drug, procainamide. 
Training programs in clinical pharmacology, particularly 
among dermatologists interested in t he problem of cutaneous 
drug reactions, are greatly needed. Extremely limited CUTrent 
efforts ru·e supported primarily by the pharmaceutical industry. 
Cooperative support by government, industry, and the aca-
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demic community is needed if advancement of knowledge in 
this complex area is to be achieved. 
Epidemiological studies. Long-term toxicity data are needed 
on all drugs. A search should be made for !lite sequelae following 
relatively limited periods of use, e.g., arsenic-induced skin can-
cers, and for long-term toxicity that occurs while the patient is 
still on a drug, e.g., fungating and vegetating halogenoderma in 
some individuals receiving iodides or bromides. Many persons 
are chronically ingesting either prescribed medication or over-
the-counter drugs. For such a person who develops an unex-
pected cutaneous reaction, methods are needed to explore cause 
and effect relationships. At present the single expedient of 
withdrawing the drug to see whether the reaction subsides is 
the clinician's imprecise solution. 
Continuing epidemiologic studies, such as the Boston Collab-
orative Drug Surveillance Program, are needed. These should 
be expanded and improved to include outpatients and those 
who medicate themselves with over-the-counter products. Con-
trol groups not receiving drugs are also needed if one is to detect 
unusual drug reaction patterns and differentiate them from 
spontaneous, nondrug associated events. In partial response to 
such needs, our government has created the Joint Commission 
on Prescription Drug Use, staffed by experts from the American 
Society of Clinical Pharmacology and the Society of Experi-
mental Medicine and Therapeutics. This group is charged with 
the responsibility of developing recommendations for ways of 
reporting patterns of use of prescription drugs, and for a system 
for postmarketing surveillance of prescription drugs, including 
accurate data on unanticipated drug toxicity and long-term 
efficacy. It is hoped that the recommendations of this group 
will be implemented, so that we may develop a better knowledge 
of the true scope of drug reactions in our population. 
Methods for treating adverse reactions. Methods are needed 
for treating drug reactions that evidence severe symptoms. 
Such methods might increase the rate of elimination of an 
offending drug or its metabolites or counteract or reverse the 
drug's adverse biologic effects. For example, ongoing work with 
the class of drugs known as the retinoids gives hope of possible 
reversal of drug-induced skin cancers. 
2. INSTRUMENTATION FOR DERMATOLOGY 
The skin forms an efficient protective barrier between the 
vulnerable internal tissues of the organism and the potentially 
injurious external environment. Many of the skin's protective 
functions rely on the physical attributes of one or the other of 
its strata. A significant physical property of the skin surface 
layers is the ability to minimize exchange of water with the 
environment. This property is often impaired in disease. Pro-
tection against mechanical stimuli relies on the hardness and 
resilience of the stratum corneum layer and the elasticity of the 
underlying dermal connective tissue. The fust line of defense 
against microbial invasion depends on the mechanical integrity 
of the stratum corneum. Its thermal resistivity helps to protect 
against heat injury. Instruments for the measurement of these 
and other physical properties, for the diagnosis of skin disease, 
for the evaluation of the activities of drugs in the skin, and for 
the treatment of skin disease by physical techniques are real-
izable with today's technology. 
Observations on the physical nature of the skin have until 
comparatively recently been subjective and anecdotal. Instru-
ments for measurement of skin physical properties have not 
been available. Clinicians noted the loss of elasticity of the skin 
with age but did not possess the background to develop tech-
niques necessary to characterize these changes. Scaliness or 
roughness and other disturbances of the horny layer, such as 
focal thickening or fissuring, have long been recognized as 
cardinal physical signs of disease, yet their significance in terms 
of altered function has not been appreciated. The pathophysi-
ologic events responsible for these alterations in the horny layer 
have been largely ignored because of difficulties in adequately 
visualizing the stratum corneum by routine light microscopy or 
even transmission electron microscopy. 
Optical characteristics of the skin (color, reflectance, etc.), 
various disturbances of pigmentation, and the altered mobility 
of the skin in scleroderma are all physical properties that were 
unexplored for many years. Inquiry into the skin's diverse 
functions and correlated physical attributes was changed by 
thoughtful and productive individuals in the post-World War 
II years. In the 1950's and 1960's there were enormous advances 
in our understanding of the functional capacity of the skin. The 
groundwork was laid for the understanding of percutaneous 
penetration. Studies of blood flow and heat loss from the skin 
surface were ushered forward and, at about the same time 
pioneers were starting to take electrical measurements of 
impedance and resistance at the skin surface and understand 
the meaning of the changes observed. Despite the quite rapid 
growth of the subject in the past 25 years, skin bioengineering 
is many years behind skin biochemistry. 
Status of Instrumentation in Dermatology 
1. Techniques for measuring epidermal properties: Breaking 
strain and elasticity. Dynamometers have been used to inves-
tigate the elasticity and breaking point of the stratum corneum 
after separation from the underlying epidermis in vitro. Al-
though this type of investigation has given valuable basic 
information, it has limitations: the possible chemical alteration 
caused by separation of the stratum corneum from the epider-
mis and alterations in SC properties due to the loss of modu-
lation from the underlying epidermis after separation and re-
striction of elasticity in the horizontal plane. A newer method 
attempts to measure the breaking strain of stratum corneum in 
the vertical plane in vivo. This may be a better way, since 
understanding intracorneal cohesion in vivo may further our 
understanding of the desquamation process. For this purpose, 
an instrument termed a "cohesograph" is used. Another indirect 
technique for measurement of intracorneal cohesion depends 
on the surface contour of the ruptured internal face of the 
stratum corneum obtained during skin surface biopsy. Ther-
momechanical analysis provides a means to compare properties 
of the SC with other materials. These have the disadvantage of 
being destructive in vitro tests besides requiring an expensive 
thermo mechanical analyzer. 
Electrical potentials. Conductance and impedance measure-
ments have been used mainly to determine the degree of 
hydration of the stratum corneum, and the instruments devised 
are a modification of the wheatstone bridge principle. A new 
method uses a sophisticated four electrode system for deter-
mination of skin resistivity. Few have attempted to measure 
the electrical potential generated within the epidermis, presum-
ably because of the difficulties encountered. A major problem 
has been the instability of baseline measurements caused by 
minor physiological changes in the skin, such as sweating or 
blood flow alterations. Increasing sophistication in electrical 
measurement may give information on the anatomical compo-
nents of skin; in particular, it may be possible to relate electrical 
measurements to the study of skin disorders. 
Permeability and water content. Permeability of the SC 
barrier-is probably the most extensively investigated of all the 
physical properties of the skin. Investigations have concen-
trated on 2 main aspects: the rate of permeability of drugs into 
the skin and the rate of transepidermal water loss (TEWL). 
The study of permeability in vivo has relied on techniques 
that measure the disappearance of substances applied to the 
skin surface or on those that measure the appearance of mate-
rial in blood or urine after their topical application. There have 
been few attempts to trace the movement of topically applied 
materials across the barrier itself. 
Electron probe microanalysis in the scanning electron micro-
scope has been used in vitro to trace the movement of elements, 
such as sulfur, lead, and zinc, across the stratum corneum; little 
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is known about the routes of penetration. Instrumentation for 
tracing substances across the stratum corneum in vivo does not 
exist. Most of our knowledge about permeability has come from 
in vitro studies of diffusion and permeability constants. 
Studies for measuring TEWL can be divided into 2 groups: 
those that use ventilated chambers in which a stream of dry air 
carries the water vapor into a measuring device (either based 
on a hygroscopic absorption, dew point detection, or infra red 
absorption) and those that use unventilated chambers contain-
ing hygroscopic substances. A new and improved technique 
measures the conductance across 2 water sensors, thus obviat-
ing the aberrations caused by changes in ambient conditions. 
In general, however, all the techniques described are cumber-
some, inefficient, and unreliable. Clearly, the state of the art of 
engineering technology has not been transferred to the prob-
lems of measuring permeability or TEWL in vivo. A relatively 
new technique, photoacoustic spectroscopy, has been devel-
oped. It is basically a spectrophotometric technique that can be 
applied to solids and depends on the excitation of the material 
to be studied by "chopped" monochromatic light in a gaseous 
atmosphere. The resultant pertubations in the material are 
amplified and analyzed as sound waves. This technique has 
been used to indicate the state of hydration of the SC, and in 
pilot studies, to measure levels of tetracycline in skin. With 
proper development, photoacoustic spectroscopy shows much 
promise as a quantitative noninvasive tool for studying concen-
trations of drugs and metabolites in vivo. Nuclear magnetic 
resonance techniques, when applied to small specimens of SC, 
are capable of producing information concerning the state of 
the bound water. Data obtained with this method indicate that 
water exists in several physical states in the stratum corneum 
and that the different states affect other physical properties. 
Surface contour. The "regular irregularities" of the normal 
skin surface were not studied quantitatively until it became 
necessary for cosmetic houses and the manufacturers of emol-
lients to provide data to support their products' claims for 
smoothing the skin and changing its properties. In the past five 
years several instruments capable of tracing and measuring 
surface contour have been produced. One is a "surfometer" for 
measurement of the surface of the ruptured interface of stratum 
corneum obtained by skin surface biopsy. The capability to 
produce hard positive replicas of the skin surface has subse-
quently enabled measurement of the true surface contour. 
Physical dimensions. The specific density ofthe SC has been 
determined by a differential floatation technique. The diameter 
and area of individual corneocytes may be estimated by direct 
or projection microscopy techniques. There is no satisfactory 
way of measuring the thickness of individual corneocytes at 
present. The thickness of the entire stratum corneum in vivo 
has recently been measured by observing the change in resist-
ance of an automatically driven steel needle . Prior to this 
innovation, this measurement had been made microscopically 
on skin sections or inferred from indirect techniques, such as 
repeated stripping. Otherwise, instrumentation in this area is 
very inadequate. 
Optical characterization. Color is a function of the architec-
ture as well as the functional state of skin. Color depends on 
melanocyte activity, the rate of blood flow, the degree of oxy-
genation of the blood, and the thickness of the epidermis and 
stratum corneum. Rapid accurate measurement of skin color 
would be immensely useful in clinical dermatology. What ex-
perimental efforts have been made in this area have been 
mainly concerned with the quantitation of erythema. Broadly, 
the techniques used have been either a color comparison or 
some modification of the reflectance spectrophotometry prin-
ciple. Reflectance from the SC has also been used to estimate 
sITlOothness of the skin surface. 
Desquamation. The rate of desquamation is dependent on 
the physical property of internal cohesion within the SC and is 
a most difficult measurement to make. The attempts that have 
been made have generally stimulated the skin surface so that 
sufficient corneocytes are available for counting. A standardized 
method for stimulating the skin surface with a "scrub appara-
tus" was recently devised. 
Surface friction. The friction of the skin surface with other 
surfaces has not been extensively explored. The work that has 
been done has demonstrated the primacy of surface moisture 
in generating frictional forces. 
Elasticity and healing strain. Standard engineering tech-
niques (dynanometers) have been used to measure elasticity 
and healing strain in samples of skin. The elastic properties of 
isolated connective tissue of small mammals have been shown 
to alter with age and after hormonal treatment. It has been 
shown that upon lineru' extension the connective tissue bundles 
become oriented in the direction of stress. The elastic properties 
of each of the fibrous components of connective tissue have 
been studied to assess their individual contribution to the tissue 
as a whole. 
Several different methods have been proposed to determine 
the elastic properties of the skin in vivo, All of the techniques 
proposed are noninvasive and all are apparently capable of 
giving accw'ate and reproducible results, although the lack of 
definitive skin "boundaries" in vivo makes interpretation diffi-
cult. 
A technique has also been devised to show how differences in 
dermal architecture might influence the propagation of shock 
waves (ballistometry). These in vivo techniques have been 
applied to changes that take place with age, during wound 
healing, and after the use of corticosteroids. 
Thiclmess. The need for methods to measure dermal thick-
ness was brought about by the widespread use of topical corti-
costeroids. With long-term application steroids can cause con-
siderable atrophy. A radiological technique that uses x-ray-
sensitive paper (xerography) rather than fllm gives a measured 
dermal image and is capable of evaluating corticosteroid atro-
phogenicity. Although the amount of radiation used is small, 
even this amount is not desirable. As an alternative, there are 
simple mechanical techniques for measuring dermal thickness; 
however, they are not as accurate as the radiological technique. 
Ultrasound technology is innovative in the measurement of 
dermal thickness and is likely to supplant others if it is found 
to be accw'ate and reproducible. 
Blood flow. Although "blood flow" is a physiological, not a 
physical property, its measurement relies on physical principles 
and on bioengineering technology. Changes in blood flow may 
alter many of the skin's physical characteristics. Early methods 
relied on thermometry or volume-change plethysmography. 
Recent ones have used the clearance of radioactive isotopes 
(such as la:lxenon) or Doppler shifting of monochromatic laser 
light. The last is pru·ticularly promising as it is noninvasive and 
can measure both tissue flow and flow through small vessels. 
3. Techniques for treatment of skin disease: Physical meth-
ods for the treatment of skin disease have been in use consid-
erably longer than techniques for the assessment of physical 
properties. Virtually all the treatment methods are destructive; 
they administer a damaging stimulus of some kind to the skin. 
The destructive stimulus may be so concentrated on a single 
point that a small area of total tissue destruction results or so 
diffuse and of such particular energy that, by penetrating only 
certain levels of the skin, the damage inflicted is more subtle at 
a cellular level. 
Heat. The application of intense heat by a point source for 
the destruction of all types of skin tumors is usually achieved 
by either directly heating a metal element (wi.re loop, metal 
ball, etc. ) with an electrical current or by generating heat within 
the tissue by the passage of a high frequency current through 
the tissue itself. Both such methods ru'e in common clinical use 
and have become sophisticated enough to control the tissue 
destruction produced and reduce the potential hazard to the 
patient. 
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High energy laser beams can be so well-controlled that they 
can destroy very small areas of tissue by their heating effect. 
Depending on the laser wave length the light will be absorbed 
strongly by one color of tissue and not by others. Consequently, 
lasers have been employed by dermatologists to selectively 
destroy areas of tissue; ruby lasers have been used to destroy 
malignant melanomata and to ablate the blue-black areas of 
tattoos. 
Cold. Freezing treatments by the local application of liquid 
nitrogen or solid carbon dioxide have been used for many years 
to treat viral warts, solar keratoses, seborrheic warts, and other 
lesions. However, it has been in only the past decade that 
instruments have been designed for this purpose; they employ 
a liquified gas, such as nitrogen or nitrous oxide, and cool a 
hollow metal probe of some kind to a very low temperature in 
order to produce their freezing effect. These instruments found 
some favor with dermatologists; they have been used more by 
other surgical specialties. 
Ultrasound. The application of high-intensity, high-fre-
quency sound waves has many medical applications. In der-
matological diagnosis ultrasound has been used to determine 
dermal thickness. In treatment, it has been employed to destroy 
small skin tumors, particularly viral warts. This type of therapy 
has as yet not been adequately evaluated. 
Ultraviolet light. Ultraviolet light (UVL) from artificial 
sources for the treatment of psoriasis and acne has been em-
ployed for many years, but only been in the past 4 years has 
attention really focused on this type of therapy with the advent 
of photochemotherapy for psoriasis. With increasing use of 
UVL has arisen ·a developing technology for producing UV and 
for measurement, and control of exposure in therapy. There is 
still uncertainty as to exactly how UVL exerts a therapeutic 
effect. However, it appears that UVL has a damaging effect on 
the epidermal cell replication and this may be the major reason 
for the therapeutic effect in psoriasis. 
Radiation. In the past radiotherapy was a frequently used 
treatment by dermatologists for both benign and malignant 
skin disease. At best the treatments produce palliation and at 
worst are hazardous. Consequently, this type of physical treat-
ment is on the "way out," and there seems little likelihood of 
its return to favor. 
Needs for Instrument Development in Dermatology 
Hepatologists, cardiologists, and hematologists are not ham-
pered by the profusion of data that greets the eye of the 
dermatologist, and this absence of "data" has encouraged these 
practitioners to apply engineering innovations to the problems 
of obtaining information on disease. Such techniques as echo-
cardiography, ultrasonic scanning, angiography, measurement 
of cell size, and viscosity are aU used to advantage and it is now 
time for dermatologists to expand their horizons and attempt 
to learn more about the organ they treat by using new technol-
ogies and advanced instrumentation. 
The late development of skin bioengineering and the limita-
tions of techniques developed so far have left much for us to 
learn about the physical properties of the skin. Very few of the 
measurement techniques described above are actually used in 
clinics to assess the changes that talle place in sllin disease or 
to assess the effect of drugs employed to treat sllin disease. 
Although some attempts have been made to link the physical 
a ttributes of skin with its structure many more studies are 
needed, especially as to how structure and physiology dynami-
cally interrelate in vivo. How, for example, does the stratum 
corneum respond to change in linear extension or acute angu-
lation? What structures of the stratum corneum are important 
in the penetration of drugs and for TEWL? 
There have been few studies concerning the relationship of 
physical properties and the biochemical status of any of the 
skin's components. It is probable that real progress will not be 
made in this area until we have the knowledge to link clinical 
and physiological events with biochemical and physical skin 
properties. Thus, there is a need to set up multidisciplinary 
groups with ·particular goals. There is also a need for the 
establishment of a regular forum for the reporting and public 
evaluation of any progress made. A journal that would regularly 
communicate advances to others in instrumentation and a 
regular series of meetings on skin bioengineering would enor-
mously aid development. 
The pressures on skin biologists, pharmacologists, and der-
matologists to develop new treatments and safe and effective 
toiletries are increasing. If these needs can be combined with 
the remarkably successful development in computer sciences, 
electronics, and engineering, then a major commitment to de-
velopment of new instrumentation for the evaluation of skin 
function and the diagnosis and treatment of skin disease could 
result. 
1. Techniques to improve diagnosis and evaluation of ther-
apy: Physical characteristics of the stratum corneum. The 
prime aim should be to establish the tensile strength, hardness, 
thermal, electrical, and optical properties by in vivo measure-
ment. It is likely that photoacoustic spectroscopy and measure-
ments of corneocyte loss will be useful in the assessment of 
both disability in skin disease and the potential for developing 
skin disease. Whatever techniques arise, they should be simple, 
accurate, inexpensive and, if possible, noninvasive. Methods 
that can assess the degree of scaliness would be useful to 
evaluate the effect of drugs designed to promote desquamation 
and to measure and record the progress of patients with scaling 
dermatoses; surface contour tracing or optical methods might 
be suitable. Accurate methods for measuring stratum corneum 
hydration would be useful for evaluation of products designed 
to increase water content. It would be helpful to be able to 
measure thickness of the stratum corneum and epidermis to-
gether and separately on intact skin. Ultrasound might be 
adapted for this purpose. 
Barrier characteristics of stratum Corneum. A simple accu-
rate instrument for the rapid measurement of transepidermal 
water loss is the most needed. Studies should be undertaken to 
identify which components of the horny layer are primarily 
responsible for the barrier property of the SC and the type of 
biochemical changes associated with barrier defects. The routes 
and rates of penetration through the stratum corneum should 
be identified for different classes of compounds. 
Physical properties of the dermis. Research on physical 
properties of the dermis should be directed toward skin elastic-
ity and dermal thickness. Much theoretical work is needed for 
the former and ultrasonic methods have become available for 
the latter. Radiological methods may complement ultrasonic 
techniques. It is likely that the xeroradiography, in particular, 
will soon be able to determine the 3 dimensional architecture 
of dermal tissues-particularly the visualization of blood vessels 
and nerves. The combination of ultrasound and xeroradiogra-
phy may also provide a method for diagnosis of inflammatory 
skin lesions and small skin tumors. 
Cutaneous circulation. Efforts must be made to develop 
techniques for the measurement of blood flow to small areas of 
skin and to the entire skin surface so that the amount of the 
cardiac output diverted to the skin during heat stress or in 
erythrodermic disease can be determined. To improve deter-
minations of oxygenation of arterial and venous blood nonin-
vasively would be immensely useful. 
It would be such a tremendous advance if vessel permeability 
in 'small areas could be determined that much effort should be 
devoted to that end. Also, increasing recognition of the involve-
ment of immune complexes in disease dictates that an effort 
must be made to find ways to detect their presence in vivo, and 
noninvasively. For instance, it might be possible to detect 
changes in small vessels by measuring flow and turbulence with 
laser Doppler techniques. 
Optical characteristics. Of primary importance is the devel-
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oprnent of a quantitative model of how light and UV radiation 
interact with skin. Such an algorithm must consider melanin 
pigmentation, the t hickness and optical constants of the various 
skin layers, and the quantity, flow rate, and state of oxygenation 
of blood in the various layers. To obtain data on these factors, 
optical and other techniques in which the skin is not invaded 
must be developed. It is reasonable to think that such an exact 
model would increase both the scope and the efficacy of clinical 
photochemotherapy and would render data from in vitro pho-
tobiologic studies valid in the design of photochemotherapy. 
Such a model also would be immediately useful for analyzing 
responses of deep tissues, blood, and lymph to ultraviolet and 
visible radiation. Techniques such as photoacoustic spectros-
copy, potentially very useful in studies to the skin, are at hand 
and little explored to this end. 
A simple, reproducible, and quantitative technique for mea-
suring and recording skin color would be immedia tely useful. 
T h e development of such a technique would make evaluation 
of t herapy more objective and management of patients very 
much less a " hit or miss" affair. Studies should include an 
attempt to determine the relative contribution of skin compo-
nent parts in determining skin color. 
What is needed in optical research is a dedicated coordinated 
effort of basic scientists, engineers, and physicians to measure 
tissu e optical constants and to apply recent advances in elec-
troop tical technology to dermatology. 
Growth characteristics. Greatly needed is a noninvasive, 
easily repeatable method to determine the growth characteris-
tics of skin tissues without the need to administer radioactively 
labeled compounds. There are 2 possibilities that should be 
explored. First, changes in the physical state of nuclei during 
cell division might be measured through the light scattering 
properties of the nuclei of the particular tissue. Recent advances 
in electro optics make this a realistic approach. Second, mea-
surement of changes in the electrical potentials generated by 
tissues during growth may prove to be a noninvasive method 
for the study of cell division in vivo. 
2. T echniques to improve screening and prognosis: It might 
be possible to identify those individuals likely to develop oc-
cupational dermatitis by preemployment screening tests of the 
physical characteristics of the stratum corneum. Also the de-
velopment and application of methods for measurement of the 
blood flow , blood oxygenation, and vessel permeability might 
allow us to predict those susceptible to stasis dermatitis and 
stasis ulceration and to determine whether surgery is needed. 
Instruments for the examination of the growth potential of 
epidermis and its vascularity should enable prediction of (1) the 
malignant potential of lesions, (2) the adequacy of ablative 
measures for skin neoplasms, and (3) the potential development 
of psoriatic lesions in relatives of psoriatics. 
3. T echniques to determine the effects of drugs: There is 
little known about the effects of drugs on skin, ·and this may 
account for the fact that there is a distressing lack of drugs that 
have a significant therapeutic effect on skin disease. These 
deficie ncies are mostly due to lack of adequate techniques to 
evaluate drug effects on cutaneous tissues. The morphological 
and biochemical means in use at the moment are of necessity 
invasive and provide little information concerning changing 
pathology and even less about changes in physiology and phys-
ical properties. 
An example of the successful use of a comparatively simple 
noninvasive mensuration technique is the "Schnell tester" cal-
ipers for the evaluation of anti-inflammatory activity of drugs. 
Another is use of xeroradiologic techniques that have enabled 
the atrophogenic action of corticosteroids to be quantitated and 
nonatrophogenic compounds to be developed. 
The range of instrumentation that might be developed to 
assis t the development of drugs for skin use is wide. The 
following are examples, and it should not be imagined that the 
list is in any way complete: (1) vascular measurements-includ-
ing rate of flow, blood oxygenation and the determination of 
the presence of immune complexes; (2) physical properties of 
stratum corneum-including hardness, elasticity, and water 
content; (3) surface properties-including contour analysis, rate 
of corneocyte loss, optical properties and fri ctional properties; 
(4) dermal physical properties, including elasticity and thick-
ness. 
4. Techniques to treat skin disease: The presently used 
physical methods to treat skin diseases should be further de-
veloped in order to provide more accurately controlled and 
more effective treatments. Destructive treatments in particular 
need refinement. Laser beams of particular wavelengths have 
all·eady been used for the destruction of melanoma. Research 
into the differential tissue absorbency of coherent light and the 
energy and wavelengths necessary to selectively destroy certain 
t issue components is needed. 
Much investigation into the effects of ultrasonic beams on 
normal and abnormal tissue is required, and the subsequent 
findings must be used to develop treatment modalities. Pigmen-
tary anomalies may be treatable by modification of present day 
phototherapy or photochemotherapy. 
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